 Home > Encyclopedia > Enoximone

Enoximone

Enoximone structure

CAS No:
77671-31-9
Formula:
C12H12N2O2S
Chemical Name:
Enoximone
Synonyms:
2H-Imidazol-2-one,1,3-dihydro-4-methyl-5-[4-(methylthio)benzoyl]-;1,3-Dihydro-4-methyl-5-[4-(methylthio)benzoyl]-2H-imidazol-2-one;MDL 17043;Fenoximone;Enoximone;RMI 17043;Perfan;Perfane
Categories:
Active Pharmaceutical Ingredients > Circulatory System Drugs

Description

Solid

Enoximone is an aromatic ketone.|Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with congestive heart failure. Trials were halted in the U.S., but the drug is used in various countries.|A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.

Enoximone Basic Attributes

Molecular Weight：

248.3

Exact Mass：

248.30

UNII：

C7Z4ITI7L7

DSSTox ID：

DTXSID8045147

ATC Code：

C - Cardiovascular system

HScode：

2933290090

Characteristics

PSA：

83.5

XLogP3：

3.72

Appearance：

light yellow solid

Density：

1.33

Melting Point：

256 °C (decomp)

Refractive Index：

1.645

Water Solubility：

DMSO: 28 mg/mL, soluble

Storage Conditions：

Store at +4°C

Safety Information

Packing level：

III

Hazard category：

6.1(b)

Transport codes：

3249

wgk germany：

Toxicity

Protein Binding：

85%

Drug Information

Drug Indication：

For the treatment of congestive heart failure.

Pharmacology：

Enoximone is a phosphodiesterase inhibitor (type III) that increases the force of contraction of the heart and dilates blood vessels. In June 2005, Myogen announced that they were discontinuing development of enoximone due to negative results. The drug is approved for use in the UK.

MeSH：

Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)|Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)|Compounds that specifically inhibit PHOSPHODIESTERASE 3. (See all compounds classified as Phosphodiesterase 3 Inhibitors.)

Absorption：

Bioavailabvility is 50% following oral administration.

Metabolism/Metabolites：

Hepatic oxidation

Biological Half-Life：

4-10 hours

Mechanism of Action：

Further research is required to determine accurately the mechanism of action of drugs with phosphodiesterase inhibitory activity, however, inhibition of PDE3 inhibits degredation of cGMP. This allows for increased NO release and vascular relaxation.

MeSH Entry Terms：

Enoximone

Enoximone Use and Manufacturing

Strong selective phosphodiesterase III inhibitors have cardiotonic and vasodilatory effects, but rarely cause symptomatic hypotension. It is used for acute and chronic congestive heart failure as well as cardiac surgery and heart failure complicated by low cardiac output.

Computed Properties

Molecular Weight:248.30
XLogP3:1.6
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:3
Rotatable Bond Count:3
Exact Mass:248.06194880
Monoisotopic Mass:248.06194880
Topological Polar Surface Area:83.5
Heavy Atom Count:17
Complexity:371
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Material

Ethyl acetate